DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Read / Leggi Disclaimer

Sangamo Therapeutics ( $SGMO ) — Q4 2025 earnings, rolling BLA progress, cash pressure and dilution risk

Sangamo Q4

Sangamo’s March 30, 2026 earnings release did not break the SGMO story. It clarified it. The company still has one asset that can genuinely change perception — ST-920 in Fabry disease — and one problem that can still overwhelm everything else — money. The clinical and regulatory side remains credible enough to keep the name alive. The balance sheet remains weak enough to keep common shareholders on a short leash.

Virgin Galactic (SPCE): why the stock jumped after earnings, what the March 30 update really changed, and what the market will watch next

virgin

Virgin Galactic’s after-hours rebound was not about a sudden return to revenue. It was about a cleaner execution story: ticket sales reopened at $750,000 per seat, the first of the new SpaceShips is moving into ground testing in April, flight testing is still targeted for Q3 2026, commercial operations remain on track for Q4 2026, and the second ship is now framed for service between late Q4 2026 and early Q1 2027. In a stock as depressed and timeline-sensitive as SPCE, that combination was enough to trigger a sharp relief move.

Encyclopedia of Social Trader Myths – Vol. 3The Self-Inflicted Edition

Myths3

The first myths of social trading usually come from outside: the trending ticker, the guru thread, the magical catalyst calendar, the cult of “smart money,” the promise that one more breakout will fix your year. But the deeper myths are the private ones. They appear after the chart turns ugly, after the timing fails, after the confidence starts cracking. That is when the internal narrator goes to work.

This third volume is about those myths. Not the noisy lies from the feed, but the polished lies traders tell themselves when they need to protect pride, postpone discomfort, and keep a bad trade emotionally alive for just a little longer. These myths sound reasonable in real time. That is exactly why they are dangerous.

Summit Therapeutics (SMMT): ELCC 2026 posters, stronger cash, and why retail is trying to rebuild the ivonescimab story

smmt2

The latest Summit update does not magically erase the old debate around overall survival, but it does add new material that retail traders and long-form biotech readers can use to reframe the case: deeper intracranial data, quality-of-life support, a visible FDA date, and a balance sheet that gives the company room to keep pushing an unusually broad ivonescimab program.

Golden Dome is no longer just a slogan: where the first real money may go

GD"

Golden Dome now looks less like a pure political slogan and more like the early framework of a real spending cycle. The most important development is not that the U.S. wants a giant missile shield in the abstract. It is that the discussion has become more operational: estimated cost has moved higher, specific capability layers have been identified for acceleration, and Reuters reported that Anduril and Palantir are working on the software layer while traditional primes such as Lockheed Martin, RTX and Northrop Grumman are involved on the industrial side.

Viridian Therapeutics ( $VRDN ): why the stock crashed on “positive” REVEAL-1 data

vrdn march30

Viridian’s REVEAL-1 press release was positive in the narrow, technical sense that matters most for binary biotech trading: the phase 3 trial hit its primary endpoint. Elegrobart, the company’s subcutaneous IGF-1R antibody for active thyroid eye disease, delivered a 54% proptosis responder rate in the every-four-week arm and 63% in the every-eight-week arm, versus 18% on placebo. The Q4W arm also showed strong diplopia data, including 51% complete resolution versus 16% on placebo. That is not failure language. That is a live asset with real activity. And yet the stock was hit as if something had gone badly wrong.

Lithium Americas ( $LAC ) DD march 30 2026

lac

Lithium Americas is no longer a story that should be read like a generic lithium exploration name. At this stage, it is much closer to a highly leveraged construction-and-financing story centered on one asset, one timetable, and one capital structure: Thacker Pass in Nevada. The company has already crossed the part of the curve where the market mainly debates whether the resource is real. That is not the core issue anymore. The resource and reserve base is already large enough to make the project strategically important, and the company now frames Thacker Pass as the largest known measured-and-indicated lithium resource and proven-and-probable reserve in the world. The market’s real question is simpler and more brutal: can management convert that geological scale into an operating business without losing control of timing, cost, or shareholder dilution?

Replimune ( $REPL) • Biotech • Oncolytic Immunotherapy

repl

Replimune is not a “nice little pipeline story” going into spring 2026. It is a high-beta, high-volatility, very real binary event name whose valuation, narrative, financing flexibility, and strategic credibility are all tied in a major way to one date: April 10, 2026. That is the FDA target action date for the resubmitted BLA for RP1 plus nivolumab in advanced melanoma after anti-PD-1 failure. The market already treated the October 2025 acceptance of the resubmission as a major event, and for good reason. This was not a routine update. It was the market’s signal that the story had gone from post-CRL damage control back to live regulatory possibility.

Altimmune ( $ALT ) May Be One of the Last Shots on Goal in the Obesity-MASH Convergence 2026

Alt march 2026

After Breakthrough Therapy Designation, 48-week IMPACT data, a financing reset and a clearer 2026 roadmap, the real question is no longer whether Altimmune can generate attention. The real question is whether pemvidutide still deserves to be viewed as one of the last relatively clean independent shots on goal at the intersection of obesity, MASH and broader metabolic-liver disease.

Perfectly Timed Trades Before Trump’s Moves . Coincidences or an Information Leak in the Market?

leaks?

In recent days, Reuters pulled together a series of episodes that, taken one by one, could look like simple strokes of luck. Seen together, however, they tell a more troubling story: extremely well-timed financial trades placed shortly before political decisions or geopolitical developments tied to the White House and capable of generating very large profits in futures, options and prediction markets.

Reuters says it has not proved a direct link between those traders and the Trump administration, but it also says the pattern is serious enough to raise hard questions and to warrant regulatory attention. That distinction matters. The story is not that wrongdoing has been proved. The story is that the timing has become too precise, too repeated and too profitable to be brushed away casually.

Nektar Therapeutics ( $NKTR ): a full deep dive March 29 2026

nektar 2026

Nektar has gone from being, for years, a biotech many investors considered tired and heavily scarred to one of the most discussed U.S. biotech stories of 2025–2026. The reason is not empty narrative. It is the combination of the clinical relaunch of rezpegaldesleukin, two dermatology indications that reignited attention, a balance sheet materially strengthened after the large February 2026 financing, and a pipeline that, while still far from commercial stage, now looks much more readable than it did just twelve months ago.

Astrotech ($ASTC ) Deep Dive — a tiny public shell wrapped around real detection technology

Astrotech

Astrotech is one of those names that can fool almost everyone at first glance. The company name still carries a legacy aerospace flavor, the ticker is tiny, the market capitalization is microscopic, and the chart can make it look like a forgotten penny stock with occasional bursts of life. But once you actually go through the filings, the press releases, the management changes, and the product portfolio, a more nuanced picture appears. Astrotech today is not really a “space” business in the way casual traders might assume. It is a commercialization vehicle built around proprietary mass spectrometry and gas chromatography platforms, with the strongest current business relevance in security screening and detection through 1st Detect, and a secondary emerging angle in field environmental testing through EN-SCAN.

SpaceX IPO Mania: Why the Internet Is Acting Like the Stock Is Already Public

Spacex ipo

The quick angle
Some companies prepare for a stock-market debut quietly. They hire banks, polish presentations, file paperwork, and wait for the financial press to notice. SpaceX is clearly not doing that. Long before a confirmed public debut, it has already turned into a giant conversation online. That alone makes the story interesting. But what makes it irresistible is the mix: rockets, Elon Musk, the promise of huge demand, and the feeling that this could become one of those rare public moments when finance starts to look like pop culture.

Wall Street weekly recap ($SPY) and next-week setup – March 30–April 3

wsr

The week that just ended was not simply another ugly week for equities. It was a deeper tightening of market tolerance. By Friday, March 27, the S&P 500 had closed at 6,368.85, the Dow at 45,166.64, the Nasdaq at 20,948.36 and the Russell 2000 at 2,449.70. The S&P 500, Dow and Nasdaq all recorded a fifth straight weekly loss, while the Dow confirmed correction territory from its February high and the Nasdaq and Russell were already there. The message was blunt: this is no longer a market that shrugs off macro stress and instantly rotates back into the same crowded stories.

Top 10 Defense-Tech Stocks to Watch – April 2026

top1' defense

Ten defense-tech names worth monitoring as drones, tactical systems, battlefield software, military electronics, training platforms and strategic infrastructure continue to reshape the market’s view of modern defense. This watchlist focuses on names with stronger retail attention, thematic clarity and visible speculative or strategic relevance.

Top 5 Space Stocks to Watch – April 2026

top 5 space april26

Why space matters again
The listed space sector has matured just enough to become interesting again, but not enough to become comfortable. That tension is exactly what makes it useful. Investors are no longer looking only at “space” as a futuristic headline. They are increasingly focusing on what part of the stack a company really owns: imagery, analytics, launch, orbital infrastructure, communications, mission execution or defense-adjacent data services.

In practice, this means the better stories are no longer the ones with the biggest cosmic vocabulary. They are the ones that can plausibly tie their business to recurring demand, sovereign capability, geospatial intelligence, communications resilience or long-duration technology relevance.

Top 10 Energy Stocks Watchlist – April 2026

top10 energy

Why this group matters now
Energy is strategic again. Oil remains essential, uranium has returned to the spotlight through energy-security and baseload-power debates, and electricity demand from industrial reshoring, AI infrastructure and grid pressure has made the sector more relevant than many investors expected.

Small-cap energy stocks are especially interesting because they can move with much more torque than large integrated names. But they also carry more fragility. The market is no longer rewarding vague resource stories as easily as before. It is rewarding names with understandable business models, workable balance sheets, visible macro exposure and a believable path to re-rating.

IOVANCE BIOTHERAPEUTICS (NASDAQ: $IOVA) March 27 2026 DD

iova march 27

Iovance enters the next stretch in a very different place than where the bull case used to live. The stock still has a powerful story behind it: AMTAGVI is already commercial, the TIL platform is no longer theoretical, and the company is trying to push that proof into larger and commercially more meaningful opportunities such as NSCLC. But this is also a company that the market punished hard when execution, European regulatory ambition and financing optics stopped matching the earlier narrative. That history matters because it explains why each new positive data point now has to pass a tougher test with investors.